| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Resistance | 56 | 2024 | 640 | 7.970 |
Why?
|
| Diabetes Mellitus, Type 2 | 61 | 2024 | 1268 | 7.960 |
Why?
|
| Blood Glucose | 39 | 2024 | 1136 | 3.680 |
Why?
|
| Insulin | 39 | 2024 | 1202 | 3.290 |
Why?
|
| Obesity | 35 | 2024 | 2239 | 3.200 |
Why?
|
| Overweight | 13 | 2024 | 364 | 2.660 |
Why?
|
| Insulin-Secreting Cells | 18 | 2020 | 146 | 2.420 |
Why?
|
| Pediatric Obesity | 11 | 2022 | 383 | 2.380 |
Why?
|
| Prediabetic State | 10 | 2024 | 57 | 2.370 |
Why?
|
| Adiposity | 10 | 2023 | 190 | 2.340 |
Why?
|
| Diabetes Mellitus, Type 1 | 13 | 2023 | 815 | 2.020 |
Why?
|
| Metformin | 15 | 2024 | 152 | 2.010 |
Why?
|
| Body Mass Index | 23 | 2024 | 1562 | 1.890 |
Why?
|
| Hypoglycemic Agents | 13 | 2024 | 444 | 1.810 |
Why?
|
| Adolescent | 94 | 2024 | 19316 | 1.790 |
Why?
|
| Glucose Tolerance Test | 19 | 2020 | 208 | 1.570 |
Why?
|
| Body Composition | 15 | 2024 | 522 | 1.430 |
Why?
|
| Cardiorespiratory Fitness | 2 | 2022 | 10 | 1.330 |
Why?
|
| Adipose Tissue | 13 | 2021 | 467 | 1.330 |
Why?
|
| Basal Metabolism | 2 | 2024 | 95 | 1.090 |
Why?
|
| Vascular Stiffness | 5 | 2022 | 72 | 1.070 |
Why?
|
| Glucose | 7 | 2023 | 879 | 1.030 |
Why?
|
| Child | 68 | 2024 | 24327 | 1.030 |
Why?
|
| Metabolic Syndrome | 7 | 2021 | 339 | 1.030 |
Why?
|
| Glucose Clamp Technique | 18 | 2021 | 76 | 1.010 |
Why?
|
| Hyperglycemia | 4 | 2023 | 225 | 0.970 |
Why?
|
| Endothelium, Vascular | 3 | 2019 | 529 | 0.960 |
Why?
|
| Calorimetry | 1 | 2024 | 62 | 0.940 |
Why?
|
| Glucose Intolerance | 8 | 2018 | 78 | 0.930 |
Why?
|
| Male | 84 | 2024 | 61419 | 0.870 |
Why?
|
| C-Peptide | 9 | 2021 | 113 | 0.870 |
Why?
|
| Female | 87 | 2024 | 66678 | 0.870 |
Why?
|
| Humans | 111 | 2024 | 124955 | 0.850 |
Why?
|
| Biomarkers | 13 | 2024 | 3084 | 0.810 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2020 | 62 | 0.800 |
Why?
|
| Obesity, Abdominal | 2 | 2012 | 37 | 0.790 |
Why?
|
| Cardiovascular Diseases | 9 | 2020 | 1959 | 0.780 |
Why?
|
| Energy Metabolism | 2 | 2024 | 767 | 0.780 |
Why?
|
| Vitamin D | 3 | 2019 | 161 | 0.770 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 119 | 0.760 |
Why?
|
| Vitamin D Deficiency | 3 | 2019 | 74 | 0.760 |
Why?
|
| Obesity, Morbid | 1 | 2023 | 185 | 0.730 |
Why?
|
| Albuminuria | 2 | 2023 | 100 | 0.670 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 3416 | 0.670 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 398 | 0.670 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 10 | 0.660 |
Why?
|
| Atherosclerosis | 3 | 2016 | 920 | 0.660 |
Why?
|
| Registries | 7 | 2020 | 1429 | 0.650 |
Why?
|
| Liraglutide | 1 | 2019 | 14 | 0.650 |
Why?
|
| Models, Biological | 1 | 2024 | 1461 | 0.640 |
Why?
|
| Drug Approval | 1 | 2019 | 43 | 0.640 |
Why?
|
| Kidney Diseases | 1 | 2023 | 478 | 0.610 |
Why?
|
| Abdominal Fat | 8 | 2012 | 19 | 0.590 |
Why?
|
| Young Adult | 24 | 2024 | 9039 | 0.570 |
Why?
|
| Health Status Disparities | 2 | 2016 | 227 | 0.550 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2018 | 58 | 0.540 |
Why?
|
| Adiponectin | 8 | 2019 | 114 | 0.540 |
Why?
|
| Sleep | 4 | 2024 | 344 | 0.520 |
Why?
|
| Endothelium | 1 | 2016 | 70 | 0.520 |
Why?
|
| Pericardium | 1 | 2016 | 83 | 0.510 |
Why?
|
| Risk Factors | 24 | 2024 | 10282 | 0.510 |
Why?
|
| Pulse Wave Analysis | 6 | 2023 | 46 | 0.490 |
Why?
|
| Heart Ventricles | 3 | 2018 | 769 | 0.480 |
Why?
|
| Peptide Hormones | 2 | 2006 | 68 | 0.470 |
Why?
|
| Hyperinsulinism | 4 | 2013 | 65 | 0.470 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2015 | 48 | 0.460 |
Why?
|
| Ventricular Function, Left | 2 | 2018 | 508 | 0.440 |
Why?
|
| Incretins | 4 | 2019 | 24 | 0.430 |
Why?
|
| Fetal Development | 1 | 2015 | 132 | 0.430 |
Why?
|
| Creatinine | 1 | 2015 | 391 | 0.430 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2005 | 281 | 0.430 |
Why?
|
| Calcinosis | 1 | 2014 | 179 | 0.410 |
Why?
|
| Puberty | 2 | 2024 | 95 | 0.400 |
Why?
|
| Body Weight | 4 | 2016 | 991 | 0.390 |
Why?
|
| Autoantibodies | 6 | 2021 | 434 | 0.390 |
Why?
|
| Absorptiometry, Photon | 7 | 2022 | 177 | 0.390 |
Why?
|
| Resistance Training | 1 | 2012 | 32 | 0.390 |
Why?
|
| Exercise | 2 | 2020 | 817 | 0.370 |
Why?
|
| Cohort Studies | 10 | 2024 | 4803 | 0.370 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 227 | 0.350 |
Why?
|
| Triglycerides | 4 | 2023 | 577 | 0.350 |
Why?
|
| Amino Acids | 3 | 2024 | 666 | 0.340 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2021 | 136 | 0.340 |
Why?
|
| Diabetic Angiopathies | 4 | 2020 | 65 | 0.330 |
Why?
|
| Diabetic Neuropathies | 1 | 2020 | 58 | 0.320 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 357 | 0.320 |
Why?
|
| Lipolysis | 2 | 2021 | 79 | 0.320 |
Why?
|
| Adult | 18 | 2024 | 29586 | 0.300 |
Why?
|
| Fasting | 7 | 2020 | 294 | 0.300 |
Why?
|
| Coronary Artery Disease | 1 | 2014 | 800 | 0.290 |
Why?
|
| Thiazoles | 2 | 2016 | 98 | 0.280 |
Why?
|
| Peptide YY | 1 | 2006 | 19 | 0.260 |
Why?
|
| Dyslipidemias | 5 | 2021 | 235 | 0.260 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 1327 | 0.250 |
Why?
|
| Heart Rate | 3 | 2023 | 589 | 0.240 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2016 | 72 | 0.240 |
Why?
|
| Intra-Abdominal Fat | 2 | 2021 | 52 | 0.240 |
Why?
|
| Liver | 1 | 2012 | 1742 | 0.240 |
Why?
|
| Prognosis | 4 | 2023 | 4633 | 0.240 |
Why?
|
| Circadian Rhythm | 2 | 2024 | 271 | 0.230 |
Why?
|
| Fluoxetine | 1 | 2024 | 43 | 0.230 |
Why?
|
| Diabetes Complications | 3 | 2024 | 202 | 0.230 |
Why?
|
| Prehypertension | 2 | 2016 | 11 | 0.230 |
Why?
|
| Sertraline | 1 | 2024 | 44 | 0.230 |
Why?
|
| Human Growth Hormone | 1 | 2024 | 74 | 0.230 |
Why?
|
| Prospective Studies | 4 | 2023 | 6141 | 0.220 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2024 | 77 | 0.220 |
Why?
|
| Child, Preschool | 4 | 2024 | 13987 | 0.220 |
Why?
|
| Body Height | 1 | 2024 | 215 | 0.210 |
Why?
|
| Alanine Transaminase | 1 | 2023 | 157 | 0.210 |
Why?
|
| Prevalence | 8 | 2020 | 2448 | 0.210 |
Why?
|
| Gene-Environment Interaction | 1 | 2023 | 121 | 0.210 |
Why?
|
| Glutamic Acid | 1 | 2024 | 203 | 0.210 |
Why?
|
| Glutamine | 1 | 2024 | 215 | 0.200 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2024 | 341 | 0.200 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2020 | 69 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 2 | 2023 | 500 | 0.200 |
Why?
|
| United States | 10 | 2020 | 10897 | 0.200 |
Why?
|
| Melatonin | 1 | 2022 | 27 | 0.190 |
Why?
|
| Regression Analysis | 5 | 2006 | 779 | 0.190 |
Why?
|
| Obesity, Metabolically Benign | 1 | 2021 | 3 | 0.190 |
Why?
|
| Pennsylvania | 4 | 2017 | 53 | 0.190 |
Why?
|
| Pasteurella Infections | 1 | 2001 | 7 | 0.180 |
Why?
|
| Pasteurella multocida | 1 | 2001 | 8 | 0.180 |
Why?
|
| Treatment Failure | 2 | 2019 | 338 | 0.180 |
Why?
|
| Self Report | 1 | 2024 | 517 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 726 | 0.180 |
Why?
|
| Muscular Dystrophies | 1 | 2001 | 52 | 0.180 |
Why?
|
| Wearable Electronic Devices | 1 | 2022 | 105 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 428 | 0.170 |
Why?
|
| Hypoglycemia | 3 | 2018 | 189 | 0.170 |
Why?
|
| Diastole | 2 | 2022 | 175 | 0.170 |
Why?
|
| Diabetic Nephropathies | 2 | 2020 | 108 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 685 | 0.170 |
Why?
|
| Energy Intake | 1 | 2023 | 493 | 0.170 |
Why?
|
| Bone Density | 1 | 2022 | 318 | 0.170 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 443 | 0.170 |
Why?
|
| Weight Loss | 1 | 2023 | 483 | 0.170 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2019 | 6 | 0.160 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2019 | 43 | 0.160 |
Why?
|
| Hyperemia | 1 | 2019 | 26 | 0.160 |
Why?
|
| Minority Groups | 2 | 2018 | 248 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 229 | 0.160 |
Why?
|
| Ideal Body Weight | 1 | 2018 | 3 | 0.160 |
Why?
|
| Nutrition Surveys | 2 | 2017 | 293 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 150 | 0.150 |
Why?
|
| Proteins | 1 | 2004 | 1036 | 0.150 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 5166 | 0.150 |
Why?
|
| Public Health | 1 | 2020 | 262 | 0.150 |
Why?
|
| Risk | 2 | 2017 | 754 | 0.140 |
Why?
|
| Viscera | 3 | 2008 | 55 | 0.140 |
Why?
|
| Pneumonia | 1 | 2001 | 323 | 0.140 |
Why?
|
| Texas | 2 | 2016 | 3585 | 0.140 |
Why?
|
| Age of Onset | 4 | 2020 | 591 | 0.140 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2016 | 6 | 0.140 |
Why?
|
| Calcifediol | 1 | 2016 | 13 | 0.140 |
Why?
|
| Reference Values | 3 | 2008 | 715 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1685 | 0.130 |
Why?
|
| Systole | 1 | 2016 | 200 | 0.130 |
Why?
|
| Hypertension | 3 | 2021 | 1329 | 0.130 |
Why?
|
| Pregnancy in Diabetics | 1 | 2015 | 19 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 459 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2019 | 3296 | 0.120 |
Why?
|
| Ghrelin | 2 | 2006 | 53 | 0.120 |
Why?
|
| Blood Pressure | 5 | 2011 | 1369 | 0.120 |
Why?
|
| Abnormalities, Multiple | 1 | 2001 | 960 | 0.120 |
Why?
|
| Albumins | 1 | 2015 | 93 | 0.120 |
Why?
|
| Seasons | 1 | 2016 | 312 | 0.120 |
Why?
|
| Mass Screening | 2 | 2018 | 783 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 697 | 0.120 |
Why?
|
| Lipids | 1 | 2018 | 521 | 0.110 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2014 | 17 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1095 | 0.110 |
Why?
|
| Pregnancy | 3 | 2015 | 7178 | 0.110 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 589 | 0.100 |
Why?
|
| Meals | 1 | 2013 | 57 | 0.100 |
Why?
|
| Islets of Langerhans | 2 | 2021 | 172 | 0.100 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 66 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2019 | 12396 | 0.100 |
Why?
|
| Patient Dropouts | 1 | 2012 | 52 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 1194 | 0.100 |
Why?
|
| Life Style | 3 | 2016 | 414 | 0.090 |
Why?
|
| Heart Atria | 1 | 2014 | 316 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2016 | 264 | 0.090 |
Why?
|
| Random Allocation | 1 | 2012 | 441 | 0.090 |
Why?
|
| Fatty Liver | 1 | 2012 | 187 | 0.090 |
Why?
|
| Adolescent Behavior | 1 | 2012 | 168 | 0.090 |
Why?
|
| Child Behavior | 1 | 2012 | 230 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 1243 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 1169 | 0.090 |
Why?
|
| Aging | 1 | 2017 | 1184 | 0.090 |
Why?
|
| Lipoproteins, HDL | 2 | 2006 | 100 | 0.080 |
Why?
|
| Fatty Acids | 1 | 2012 | 347 | 0.080 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2008 | 19 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2011 | 2100 | 0.070 |
Why?
|
| Testosterone | 1 | 2013 | 533 | 0.070 |
Why?
|
| Abdomen | 1 | 2008 | 127 | 0.070 |
Why?
|
| Comorbidity | 3 | 2018 | 1531 | 0.070 |
Why?
|
| Disease Progression | 3 | 2018 | 2062 | 0.070 |
Why?
|
| Depression | 1 | 2015 | 1236 | 0.070 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 41 | 0.070 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2006 | 17 | 0.070 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2006 | 29 | 0.070 |
Why?
|
| Time Factors | 3 | 2024 | 6328 | 0.060 |
Why?
|
| Physical Fitness | 1 | 2006 | 90 | 0.060 |
Why?
|
| Estradiol | 1 | 2008 | 532 | 0.060 |
Why?
|
| Waist-Hip Ratio | 1 | 2006 | 56 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 947 | 0.060 |
Why?
|
| Leptin | 2 | 2023 | 214 | 0.060 |
Why?
|
| Phenotype | 3 | 2023 | 4260 | 0.060 |
Why?
|
| Anthropometry | 1 | 2016 | 198 | 0.060 |
Why?
|
| Pediatrics | 2 | 2018 | 1148 | 0.060 |
Why?
|
| ROC Curve | 3 | 2015 | 569 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 2635 | 0.050 |
Why?
|
| Sample Size | 1 | 2023 | 86 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 872 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 145 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2023 | 233 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 2905 | 0.050 |
Why?
|
| Actigraphy | 1 | 2022 | 45 | 0.050 |
Why?
|
| Light | 1 | 2022 | 176 | 0.050 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2021 | 24 | 0.050 |
Why?
|
| Ear | 1 | 2001 | 25 | 0.050 |
Why?
|
| Hair | 1 | 2001 | 24 | 0.050 |
Why?
|
| Mouth Abnormalities | 1 | 2001 | 15 | 0.050 |
Why?
|
| Aging, Premature | 1 | 2001 | 30 | 0.050 |
Why?
|
| Toes | 1 | 2001 | 28 | 0.050 |
Why?
|
| Animals, Domestic | 1 | 2001 | 31 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2023 | 472 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 2885 | 0.040 |
Why?
|
| Fingers | 1 | 2001 | 65 | 0.040 |
Why?
|
| Life History Traits | 1 | 2020 | 5 | 0.040 |
Why?
|
| Micrognathism | 1 | 2001 | 65 | 0.040 |
Why?
|
| Behavioral Medicine | 1 | 2020 | 10 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3572 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 1697 | 0.040 |
Why?
|
| Nose | 1 | 2001 | 93 | 0.040 |
Why?
|
| Echocardiography | 2 | 2018 | 1053 | 0.040 |
Why?
|
| Saliva | 1 | 2001 | 114 | 0.040 |
Why?
|
| Dogs | 1 | 2001 | 774 | 0.040 |
Why?
|
| Middle Aged | 3 | 2020 | 26900 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 112 | 0.040 |
Why?
|
| Cleft Palate | 1 | 2001 | 140 | 0.040 |
Why?
|
| Autonomic Nervous System | 1 | 2019 | 48 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 143 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2021 | 16303 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 2523 | 0.040 |
Why?
|
| Syndrome | 1 | 2001 | 1121 | 0.040 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2018 | 19 | 0.040 |
Why?
|
| Adolescent Medicine | 1 | 2018 | 22 | 0.040 |
Why?
|
| Diabetic Retinopathy | 1 | 2020 | 154 | 0.040 |
Why?
|
| Diet Therapy | 1 | 2018 | 41 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2017 | 29 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2018 | 82 | 0.030 |
Why?
|
| Animals | 2 | 2013 | 34221 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 120 | 0.030 |
Why?
|
| Health Promotion | 1 | 2020 | 389 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 248 | 0.030 |
Why?
|
| Gynecology | 1 | 2018 | 123 | 0.030 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2016 | 19 | 0.030 |
Why?
|
| Inflammation | 2 | 2018 | 1442 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2018 | 153 | 0.030 |
Why?
|
| Glucagon | 1 | 2016 | 182 | 0.030 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2018 | 160 | 0.030 |
Why?
|
| Austria | 1 | 2015 | 19 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8192 | 0.030 |
Why?
|
| Endocrinology | 1 | 2018 | 134 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 65 | 0.030 |
Why?
|
| Medical Records | 1 | 2016 | 192 | 0.030 |
Why?
|
| Stillbirth | 1 | 2015 | 79 | 0.030 |
Why?
|
| E-Selectin | 1 | 2014 | 41 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 869 | 0.030 |
Why?
|
| Heart | 1 | 2019 | 729 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 694 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 76 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 570 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 307 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2014 | 141 | 0.030 |
Why?
|
| Ventricular Dysfunction | 1 | 2014 | 25 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2819 | 0.030 |
Why?
|
| Atrial Function, Left | 1 | 2014 | 27 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 314 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2014 | 180 | 0.030 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 109 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 605 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 240 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2015 | 252 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2015 | 347 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 2061 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2015 | 473 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2024 | 4530 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 336 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1638 | 0.020 |
Why?
|
| Carnitine | 1 | 2012 | 74 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 682 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 732 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2009 | 19 | 0.020 |
Why?
|
| Immunoassay | 1 | 2009 | 130 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 2428 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 345 | 0.020 |
Why?
|
| Body Size | 1 | 2007 | 55 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2164 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2011 | 759 | 0.020 |
Why?
|
| Proinsulin | 1 | 2006 | 10 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2006 | 47 | 0.020 |
Why?
|
| Infant | 1 | 2001 | 12455 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2006 | 306 | 0.020 |
Why?
|
| Exercise Test | 1 | 2006 | 254 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 555 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1884 | 0.010 |
Why?
|
| Family | 1 | 2005 | 565 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 2054 | 0.010 |
Why?
|
| Diet | 1 | 2005 | 1141 | 0.010 |
Why?
|